Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.34 |
| ▸ | PDE1A | P54750 | 5/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.34 |
| ▸ | PDE9A | O76083 | 3/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083378 | 0.81 | LRRK2 (0.46) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL17083393 | 0.80 | PDE4D (0.43) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL16985290 | 0.76 | LRRK2 (0.39) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL24813414 | 0.72 | MAPK8 (0.35) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL24813839 | 0.72 | PDE9A (0.36) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL24812192 | 0.72 | LRRK2 (0.35) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL21848989 | 0.72 | MGLL (0.30) | — | |
| SCHEMBL16985276 | 0.72 | LRRK2 (0.38) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL25832866 | 0.71 | LRRK2 (0.41) | LRRK2PDE4DPDE1CPDE1APDE1B | |
| SCHEMBL18701534 | 0.70 | PDK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885PDE4D 944/4885PDE1C 1207/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885PDE4D 944/4885PDE1C 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.